1. Home
  2. BCHT vs ICCC Comparison

BCHT vs ICCC Comparison

Compare BCHT & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BCHT

Birchtech Corp. Common Stock

N/A

Current Price

$1.62

Market Cap

55.0M

Sector

Industrials

ML Signal

N/A

Logo ImmuCell Corporation

ICCC

ImmuCell Corporation

HOLD

Current Price

$7.98

Market Cap

64.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCHT
ICCC
Founded
N/A
1982
Country
United States
United States
Employees
15
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.0M
64.0M
IPO Year
2026
1995

Fundamental Metrics

Financial Performance
Metric
BCHT
ICCC
Price
$1.62
$7.98
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$15.00
N/A
AVG Volume (30 Days)
96.2K
20.9K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
53.85
EPS
N/A
N/A
Revenue
N/A
$26,493,169.00
Revenue This Year
$13.42
N/A
Revenue Next Year
$61.22
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
51.64
52 Week Low
$1.61
$4.52
52 Week High
$2.45
$7.82

Technical Indicators

Market Signals
Indicator
BCHT
ICCC
Relative Strength Index (RSI) 30.60 75.44
Support Level N/A $5.78
Resistance Level $2.33 N/A
Average True Range (ATR) 0.18 0.34
MACD -0.01 0.16
Stochastic Oscillator 7.06 100.00

Price Performance

Historical Comparison
BCHT
ICCC

About BCHT Birchtech Corp. Common Stock

Birchtech Corp is a provider of specialty activated carbon technologies, delivering solutions for air and water purification. It provides patented and proprietary Sorbent Enhancement Additive (SEA) technologies for mercury emissions capture to the coal-fired utility sector, and is developing water purification technologies with a specialization on forever chemicals such as PFAS and PFOS. Geographically, the company derives all of its revenue from the United States.

About ICCC ImmuCell Corporation

ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.

Share on Social Networks: